(-)-Epigallocatechin gallate inhibits growth and activation of the VEGF/VEGFR axis in human colorectal cancer cells

Chemico-Biological Interactions

Volumn 185, Issue 3, 2010, Pages 247-252

  Shimizu, Masahito ^a   Shirakami, Yohei ^a   Sakai, Hiroyasu ^a   Yasuda, Yoichi ^a   Kubota, Masaya ^a   Adachi, Seiji ^a   Tsurumi, Hisashi ^a   Hara, Yukihiko ^b   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Hara Office Inc   (Japan)

Author keywords

Colon cancer; EGCG; VEGF VEGFR axis

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIGALLOCATECHIN GALLATE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE 1; NEU DIFFERENTIATION FACTOR; PROTEIN KINASE B; SOMATOMEDIN B; SOMATOMEDIN C; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; CATECHIN; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER CELL; CANCER CELL CULTURE; COLORECTAL CANCER; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; CELL STRAIN CACO 2; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL TUMOR; DRUG ANTAGONISM; METABOLISM; TUMOR CELL LINE;

MUS MUSCULUS;

ANTICARCINOGENIC AGENTS; CACO-2 CELLS; CATECHIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; HCT116 CELLS; HT29 CELLS; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952299666     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.03.036     Document Type: Article

References (31)

1. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
2. Ellis L.M., Hicklin D.J. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat. Rev. Cancer 2008, 8:579-591.
3. Cascinu S., Staccioli M.P., Gasparini G., Giordani P., Catalano V., Ghiselli R., Rossi C., Baldelli A.M., Graziano F., Saba V., Muretto P., Catalano G. Expression of vascular endothelial growth factor can predict event-free survival in stage II colon cancer. Clin. Cancer Res. 2000, 6:2803-2807.
4. Giatromanolaki A., Koukourakis M.I., Sivridis E., Chlouverakis G., Vourvouhaki E., Turley H., Harris A.L., Gatter K.C. Activated VEGFR2/KDR pathway in tumour cells and tumour associated vessels of colorectal cancer. Eur. J. Clin. Invest. 2007, 37:878-886.
5. Wolpin B.M., Mayer R.J. Systemic treatment of colorectal cancer. Gastroenterology 2008, 134:1296-1310.
6. Yang C.S., Maliakal P., Meng X. Inhibition of carcinogenesis by tea. Annu. Rev. Pharmacol. Toxicol. 2002, 42:25-54.
7. Yang C.S., Wang X., Lu G., Picinich S.C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009, 9:429-439.
8. Shimizu M., Fukutomi Y., Ninomiya M., Nagura K., Kato T., Araki H., Suganuma M., Fujiki H., Moriwaki H. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol. Biomarkers Prev. 2008, 17:3020-3025.
9. Shimizu M., Deguchi A., Lim J.T., Moriwaki H., Kopelovich L., Weinstein I.B. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor-2 signaling pathways in human colon cancer cells. Clin. Cancer Res. 2005, 11:2735-2746.
10. Shimizu M., Deguchi A., Joe A.K., McKoy J.F., Moriwaki H., Weinstein I.B. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J. Exp. Ther. Oncol. 2005, 5:69-78.
11. Shimizu M., Deguchi A., Hara Y., Moriwaki H., Weinstein I.B. EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells. Biochem. Biophys. Res. Commun. 2005, 334:947-953.
12. Lamy S., Gingras D., Beliveau R. Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation. Cancer Res. 2002, 62:381-385.
13. Shirakami Y., Shimizu M., Adachi S., Sakai H., Nakagawa T., Yasuda Y., Tsurumi H., Hara Y., Moriwaki H. (-)-Epigallocatechin gallate suppresses the growth of human hepatocellular carcinoma cells by inhibiting activation of the vascular endothelial growth factor-vascular endothelial growth factor receptor axis. Cancer Sci. 2009, 100:1957-1962.
14. Fukuda R., Hirota K., Fan F., Jung Y.D., Ellis L.M., Semenza G.L. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 2002, 277:38205-38211.
15. Laughner E., Taghavi P., Chiles K., Mahon P.C., Semenza G.L. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol. Cell Biol. 2001, 21:3995-4004.
16. Zhong H., Chiles K., Feldser D., Laughner E., Hanrahan C., Georgescu M.M., Simons J.W., Semenza G.L. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 2000, 60:1541-1545.
17. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., Buechler P., Isaacs W.B., Semenza G.L., Simons J.W. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999, 59:5830-5835.
18. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., Dillehay L.E., Madan A., Semenza G.L., Bedi A. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 2000, 14:34-44.
19. Wang Z.Y., Agarwal R., Bickers D.R., Mukhtar H. Protection against ultraviolet B radiation-induced photocarcinogenesis in hairless mice by green tea polyphenols. Carcinogenesis 1991, 12:1527-1530.
20. Gupta S., Hastak K., Ahmad N., Lewin J.S., Mukhtar H. Inhibition of prostate carcinogenesis in TRAMP mice by oral infusion of green tea polyphenols. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10350-10355.
21. Shimizu M., Shirakami Y., Sakai H., Adachi S., Hata K., Hirose Y., Tsurumi H., Tanaka T., Moriwaki H. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev. Res. 2008, 1:298-304.
22. Yasuda Y., Shimizu M., Sakai H., Iwasa J., Kubota M., Adachi S., Osawa Y., Tsurumi H., Hara Y., Moriwaki H. (-)-Epigallocatechin gallate prevents carbon tetrachloride-induced rat hepatic fibrosis by inhibiting the expression of the PDGFRbeta and IGF-1R. Chem. Biol. Interact. 2009, 182:159-164.
23. Shimizu M., Shirakami Y., Sakai H., Tatebe H., Nakagawa T., Hara Y., Weinstein I.B., Moriwaki H. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 2008, 262:10-18.
24. Zhang Q., Tang X., Lu Q., Zhang Z., Rao J., Le A.D. Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol. Cancer Ther. 2006, 5:1227-1238.
25. Kondo T., Ohta T., Igura K., Hara Y., Kaji K. Tea catechins inhibit angiogenesis in vitro, measured by human endothelial cell growth, migration and tube formation, through inhibition of VEGF receptor binding. Cancer Lett. 2002, 180:139-144.
26. Rodriguez S.K., Guo W., Liu L., Band M.A., Paulson E.K., Meydani M. Green tea catechin, epigallocatechin-3-gallate, inhibits vascular endothelial growth factor angiogenic signaling by disrupting the formation of a receptor complex. Int. J. Cancer 2006, 118:1635-1644.
27. Jung Y.D., Kim M.S., Shin B.A., Chay K.O., Ahn B.W., Liu W., Bucana C.D., Gallick G.E., Ellis L.M. EGCG, a major component of green tea, inhibits tumour growth by inhibiting VEGF induction in human colon carcinoma cells. Br. J. Cancer 2001, 84:844-850.
28. Feldser D., Agani F., Iyer N.V., Pak B., Ferreira G., Semenza G.L. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res. 1999, 59:3915-3918.
29. Cascio S., Ferla R., D'Andrea A., Gerbino A., Bazan V., Surmacz E., Russo A. Expression of angiogenic regulators, VEGF and leptin, is regulated by the EGF/PI3K/STAT3 pathway in colorectal cancer cells. J. Cell. Physiol. 2009, 221:189-194.
30. Fukuda R., Kelly B., Semenza G.L. Vascular endothelial growth factor gene expression in colon cancer cells exposed to prostaglandin E2 is mediated by hypoxia-inducible factor 1. Cancer Res. 2003, 63:2330-2334.
31. Lambert J.D., Kennett M.J., Sang S., Reuhl K.R., Ju J., Yang C.S. Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice. Food Chem. Toxicol. 2010, 48:409-416.